Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer February 20, 2018December 14, 2022 Arthur N. Brodsky, PhD
Preview Immunotherapy Highlights from AACR 2018 Annual Meeting April 12, 2018December 14, 2022 Arthur N. Brodsky, PhD